Patrick S.Belville

Partner

(T) 1.313.230.7970

Patrick Belville's practice includes domestic and cross-border mergers and acquisitions, private equity and venture capital transactions, restructurings, recapitalizations, joint ventures, strategic alliances, and corporate governance. His M&A experience includes contested takeovers and section 363 asset acquisitions.

Patrick has advised companies in a wide range of industries, including: health care (medical and pharmaceutical product manufacturing, distribution, and services), electronics and other technologies, airlines, software, waste disposal and recycling, cogeneration and renewable energy, oil and gas pipelines, beverages, chemicals, automotive, construction and farm equipment, advertising, education, and outdoor/sports equipment.

In addition to traditional corporate transactions, Patrick has represented various parties in domestic and cross-border leasing transactions involving heavy equipment, power plants, light rail, railcars and locomotives, manufacturing facilities, office complexes, high-speed ferries, corporate and commercial aircraft, and other large assets.

Prior to rejoining Jones Day in 2018, Patrick served as vice president and associate general counsel, M&A, at Cardinal Health, a long-time Jones Day client, where he closed more than $10 billion in acquisitions, divestitures, and other strategic transactions.

Patrick is a member of the American Bar Association.

Experience

  • Adtalem Global Education acquires OnCourse Learning's financial services business for $121 millionJones Day advised Adtalem Global Education Inc., a leading workforce solutions provider, in its acquisition of the financial services division of OnCourse Learning, a Brookfield, Wisconsin-based leading provider of compliance training, licensure preparation, continuing education and professional development, for approximately $121 million in cash.
  • Cardinal Health sells majority stake in NaviHealth to Clayton, Dubilier & RiceJones Day advised Cardinal Health, Inc. (NYSE: CAH) in the sale of a majority stake in its NaviHealth business to funds managed by Clayton, Dubilier & Rice.
  • Cardinal Health sells its Cardinal Health China distribution business to Shanghai Pharmaceuticals for $1.2 billionJones Day advised Cardinal Health in the $1.2 billion sale of its Cardinal Health China distribution business to Shanghai Pharmaceuticals Holding Co., Ltd.
  • Cardinal Health acquires leading patient product portfolio from Medtronic for $6.1 billionJones Day advised Cardinal Health on the acquisition of Medtronic's Patient Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses for $6.1 billion in cash.
  • Cardinal Health acquires rights to Lymphoseek® from Navidea BiopharmaceuticalsJones Day advised Cardinal Health in its acquisition of Navidea Biopharmaceuticals' rights to Lymphoseek® in North America for lymphatic mapping, lymph node biopsy, and the diagnosis of metastatic spread to lymph nodes for the staging of cancer.
  • naviHealth acquires CuraspanJones Day advised naviHealth Inc., a Cardinal Health company, in its acquisition of Curaspan Health Group Inc., a privately held leading provider of care transition tools for hospitals and post-acute healthcare providers.
  • naviHealth acquires RightCare SolutionsJones Day represented Cardinal Health and its subsidiary, naviHealth, Inc., in connection with the acquisition of RightCare Solutions, Inc., a health care decision support software service provider specializing in hospital discharge planning software and readmissions management.
  • Cardinal Health acquires Cordis for $1.9 billionJones Day advised Cardinal Health, Inc. in its acquisition of Johnson & Johnson's Cordis business, a leading global manufacturer of cardiology and endovascular devices, for $1.9 billion in cash.
  • Cardinal Health acquires controlling interest in naviHealth for $290 millionJones Day advised Cardinal Health, Inc. in its $290 million acquisition of a controlling interest in naviHealth, a company that partners with health plans, health systems, and providers to manage the post-acute care of patients, including as a leading convener for health systems in the Centers for Medicare and Medicaid Services' Bundled Payments for Care Improvement initiative.
  • Cardinal Health acquires The Harvard Drug Group for $1.115 billionJones Day advised Cardinal Health in its acquisition of The Harvard Drug Group, a distributor of generic pharmaceuticals, over-the-counter medications, and related products to retail, institutional, and alternate care customers from Court Square Capital Partners for $1.115 billion.
  • Cardinal Health acquires Tradex InternationalJones Day advised Cardinal Health, Inc. on the acquisition of Tradex International, Inc., a Cleveland based distributor of latex and other gloves used primarily in the health care and food service industries.
  • Cardinal Health enters long-term strategic agreement with Henry Schein and sells certain physician office distribution business assetsJones Day advised Cardinal Health, Inc. with the sale of certain assets associated with its physician office distribution business to Henry Schein, Inc. and with an exclusive long-term distribution agreement with Schein to provide one of the most comprehensive service and product offerings to office-based medical practices.
  • Richland-Stryker Investment sells Richland-Stryker Generation to Energy Capital PartnersJones Day advised RichlandStryker Investment in its sale of Richland-Stryker Generation, which includes a 444 MW gas- and oil-fired unit in Defiance, Ohio, and a 20 MW oil-fired facility in Stryker, Ohio to Energy Capital Partners.
  • Richland-Stryker, a unit of Quintana Minerals Corporation, acquires two gas-fired peaking facilities from First EnergyJones Day advised Quintana, an investment partnership based in Texas, through its subsidiary, Richland-Stryker Generation LLC, in the acquisition of two gas-fired peaking facilities, the Richland Generation Station and the Stryker Generation Station, from FirstEnergy Corp.
  • Potash Corporation successfully defends historic $43.1 billion hostile takeover bidFollowing an arduous three-month battle, Jones Day's client, Potash Corporation of Saskatchewan, Inc., successfully repelled BHP Billiton's hostile $43.1 billion tender offer for all of PotashCorp's shares in November 2010.
  • Energy fund negotiates 20-year gas transportation agreement in connection with sale of pipelineEnergy fund negotiates 20-year gas transportation agreement in connection with sale of pipeline.
  • Woodward acquires HR Textron Inc. from Textron Inc. for $365 millionJones Day advised Woodward, Inc. in its $365 million acquisition of HR Textron Inc. from Textron Inc. HR Textron is an industry leader in the advanced technology, engineering development, and manufacturing of mission-critical actuation systems and controls for weapons, aircraft, turbine engines, and combat vehicles.
  • Abbott acquires Advanced Medical Optics for $2.8 billionJones Day advised Abbott Laboratories in its $2.8 billion acquisition of Advanced Medical Optics, Inc. (AMO), a manufacturer of ophthalmic care products, comprised of three segments: cataract surgery, laser vision correction (LASIK), and eye care products.
  • Lakeside Energy and InEnTec create new company to help build sustainable future for chemical industryJones Day advised Lakeside Energy, LLC in the formation of and acquisition of a controlling interest in InEnTec Chemical, LLC, a joint venture with InEnTec, LLC to facilitate construction of commercial scale Plasma Enhanced Melter (PEM(TM) gasification facilities that will convert hazardous waste and chemical residuals into useful chemical products.
  • Woodward acquires MotoTronJones Day advised Woodward, Inc. in its acquisition of all of the outstanding capital stock of MotoTron Corporation and the intellectual property assets owned by its parent company, Brunswick Corporation, that are used in connection with the MotoTron business.
  • We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.